<div style="position: relative; display: block; max-width: 100%;"><div style="padding-top: 56.25%;"><iframe src="//players.brightcove.net/4365621440001/216a41e4-093d-49b1-831c-dbf5b8ca99d9_default/index.html?videoId=6029022259001" <!-- [et_pb_line_break_holder] -->allowfullscreen <!-- [et_pb_line_break_holder] -->webkitallowfullscreen <!-- [et_pb_line_break_holder] -->mozallowfullscreen <!-- [et_pb_line_break_holder] -->allow="encrypted-media" <!-- [et_pb_line_break_holder] -->style="position: absolute; top: 0px; right: 0px; bottom: 0px; left: 0px; width: 100%; height: 100%;"></iframe></div></div><!-- [et_pb_line_break_holder] -->
Department of Medicine Grand Rounds
June 12, 2018
“Bench to Bedside: Mechanism-based treatments for hemoglobinopathies”
Gregory J. Kato, MD
Professor of Medicine, Division of Hematology/Oncology
Director, Adult Sickle Cell Center of Excellence
Heart, Lung, Blood and Vascular Medicine Institute University of Pittsburgh School of Medicine
Mitchell J. Weiss, MD, PhD
Chairman, Department of Hematology
Arthur Nienhuis Endowed Chair in Hematology St. Jude Children’s Research Hospital
